CHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS Williams Hematology CHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS STEPHEN M. BAIRD Definition and History Plasma Cell Neoplasms Essential Monoclonal Gammopathy Chronic Cold Agglutinin Syndrome Cryoglobulins Transient M Proteins Etiology and Pathogenesis Genetic Background Chromosomal Anomalies Cytokines Laboratory Features Surface Markers Zonal Electrophoresis Immunoelectrophoresis and Immunofixation Electrophoresis Immunoglobulin…
SUMMARY Plasma cell neoplasms are tumors derived from an expansion of mutated mature B-cells and their precursors. These neoplasms include essential monoclonal gammopathy (synonym: monoclonal gammopathy of unknown significance; Chap. 106), smoldering myeloma (Chap. 107), myeloma (Chap. 107), solitary and extramedullary plasmacytomas (Chap. 107), light-chain amyloidosis (Chap. 108), and Waldenström macroglobulinemia (Chap. 109). The prototype of a malignant plasma cell neoplasm is myeloma, which is characterized by complex genetic alterations, best assessed by metaphase cytogenetics, fluorescence in situ hybridization analysis, and gene-expression profiling. The genetic changes are more akin to solid tumors than to hematologic malignancies. Interactions between myeloma cells and the marrow microenvironment affect the survival, proliferation, and drug resistance of myeloma cells, and the development of osteoporosis or osteolysis, which is a hallmark of myeloma. As in most malignancies, a cancer ...
TY - JOUR. T1 - Low-grade Epstein-Barr virus positive plasma cell proliferations of precursor plasma cell origin. T2 - Report of two cases. AU - Oaxaca, Gabriel G.. AU - Coffey, Amy M. AU - Gannon, Francis H.. AU - Szigeti, Reka. PY - 2017/7/30. Y1 - 2017/7/30. N2 - B cell lymphoproliferative disorders with plasmacytic differentiation are a spectrum of neoplasms arising from B cells in different stages of maturation, which include marginal zone lymphoma, plasmablastic lymphoma, ALK-positive diffuse large B cell lymphoma, primary effusion lymphoma, and plasma cell neoplasms. Within this group, Epstein-Barr virus (EBV) is mostly linked to plasmablastic lymphoma and primary effusion lymphoma. EBV has only rarely been associated with the remaining entities and occurs almost exclusively in immunocompromised patients. We report two cases of EBV positive, mature appearing plasma cell proliferations without previously identified immunodeficiency. The proliferating plasma cells showed co-expression of ...
Fingerprint Dive into the research topics of Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. Together they form a unique fingerprint. ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
TY - JOUR. T1 - Plasmacytoma and plasma cell myeloma affecting the jaws: A multi-institutional collaborative study. AU - Souza, Lucas Lacerda de. AU - Cáceres, Cinthia Verónica Bardález López de. AU - Vargas, Pablo Agustin. AU - Lopes, Márcio Ajudarte. AU - Santos-Silva, Alan Roger. AU - Silva, Wagner Gomes da. AU - Prado-Ribeiro, Ana Carolina. AU - Brandão, Thais Bianca. AU - Pereira, Juliana. AU - Mesquita, Ricardo Alves. AU - Pontes, Flávia Sirotheau Correa. AU - González-Arriagada, Wilfredo Alejandro. AU - Pedraza, Ricardo Martinez. AU - Andrade, Bruno Augusto Benevenuto de. AU - Romañach, Mario José. AU - Soares, Ciro Dantas. AU - Carvalho, Maria Goretti Freire de. AU - Pires, Fabio Ramôa. AU - Carlos, Roman. AU - Fonseca, Felipe Paiva. AU - Pontes, Hélder Antônio Rebelo. AU - de Almeida, Oslei Paes. N1 - © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.. PY - 2021/7. Y1 - 2021/7. N2 - BACKGROUND: Plasma cell neoplasms are characterized by the proliferation of ...
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm characterized by proliferation of neoplastic plasma cells in bone marrow (BM). So fa
Immunoglobulin G (IgG) is an antibody isotype secreted by plasma cells and composed of four peptide chains - two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers (1). In humans, IgG consists of four subclasses that differ only marginally in their amino acid composition (1). Representing approximately 75% of serum immunoglobulins in humans, IgG is the most abundant antibody isotype found in the circulation (1). Anti-IgG had been proven useful in the assessment of renal biopsies (2), autoimmune disorders (3), in the identification of plasma cell neoplasms (4) and in non-Hodgkin lymphomas (5). The ratio of IgG4+ plasma cells to IgG+ plasma cells has been considered important in making a diagnosis of IgG4-related disorders (6).. ...
Motivation: Standard laboratory classification of the plasma cell dyscrasia monoclonal gammopathy of undetermined significance (MGUS) and the overt plasma cell neoplasm multiple myeloma (MM) is quite accurate, yet, for the most part, biologically uninformative. Most, if not all, cancers are caused by inherited or acquired genetic mutations that manifest themselves in altered gene expression patterns in the clonally related cancer cells. Microarray technology allows for qualitative and quantitative measurements of the expression levels of thousands of genes simultaneously, and it has now been used both to classify cancers that are morphologically indistinguishable and to predict response to therapy. It is anticipated that this information can also be used to develop molecular diagnostic models and to provide insight into mechanisms of disease progression, e.g., transition from healthy to benign hyperplasia or conversion of a benign hyperplasia to overt malignancy. However, standard data analysis ...
Multiple myeloma (plasma cell neoplasm) is a rare type of cancer that results in the uncontrolled production of one type of white blood cell (plasma cell) in the bone marrow. The cancer cells can crowd out normal blood cells, causing a reduction in red blood cells (anemia). The overproduction of plasma cells causes an...
Multiple myeloma, plasmacytoma, lymphoplasmacytic lymphoma, and monoclonal gammopathy of undetermined significance (MGUS) are different types of plasma cell neoplasms. Find out about risk factors, symptoms, tests to diagnose, prognosis, stages, and treatment for these diseases.
PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as NCIs PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary]. The best way to cite this PDQ summary is: PDQ® Adult Treatment Editorial Board. PDQ Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment. Bethesda, MD: National Cancer Institute. Updated ,MM/DD/YYYY,. Available at: https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq. Accessed ,MM/DD/YYYY,. [PMID: 26389437] Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It ...
To better understand the role of individual and lifestyle factors in human disease, an exposome-wide association study was performed to investigate within a single-study anthropometry measures and lifestyle factors previously associated with B-cell lymphoma (BCL). Within the European Prospective Investigation into Cancer and nutrition study, 2402 incident BCL cases were diagnosed from 475 426 participants that were followed-up on average 14 years. Standard and penalized Cox regression models as well as principal component analysis (PCA) were used to evaluate 84 exposures in relation to BCL risk. Standard and penalized Cox regression models showed a positive association between anthropometric measures and BCL and multiple myeloma/plasma cell neoplasm (MM). The penalized Cox models additionally showed the association between several exposures from categories of physical activity, smoking status, medical history, socioeconomic position, diet and BCL and/or the subtypes. PCAs confirmed the ...
Plasma cell neoplasms (PCN), including multiple myeloma, are tumors of terminally differentiated B cells. Despite a significant research effort, and numerous advances in therapy, most tumors of this B cell lineage remain incurable. To this end, understanding factors which are critical for the development of PCN may lead to new avenues for therapy. Interleukin-6 (IL-6) is a pleiotropic, pro-inflammatory cytokine which supports the growth, proliferation, and survival of myeloma cells. We found that inflammation, and in particular, IL-6 is critical for the development of PCN. In order to determine if tumor microenvironment (TME) or B cell-derived IL-6 was more important in PCN development, we utilized an adoptive transfer system of tumor formation. By adoptively transferring premalignant B cells into recipients, and then providing the B cells with an inflammatory microenvironment through the use of pristane, we were able to generate donor tumors in recipient mice. Utilizing this method, a series of
Potential symptoms of plasma cell neoplasms include fatigue, bone pain, weakness and fevers, says the National Cancer Institute. Brittle, easily breakable bones are also present in some cases....
Contents: Preface; Part I. Diagnostic Techniques: 1. Morphology Wendy N. Erber; 2. Immunocytochemistry Wendy N. Erber; 3. Flow cytometry Maryalice Stetler-Stevenson and Constance M. Yuan; 4. Cytogenetics Christine J. Harrison and Claire Schwab; 5. Molecular genetics Ken Mills; Part II. Hematological Malignancies: 6. The integrated approach to the diagnosis of hematological malignancies Mike A. Scott and Wendy N. Erber; 7. Acute lymphoblastic leukemia Elaine Coustan-Smith and Dario Campana; 8. Acute myeloid leukemia David Grimwade; 9. Mature B cell leukemias Constantine S. Tam and Michael J. Keating; 10. Mature T cell and natural killer-cell leukemias Kaaren K. Reichard and Kathryn Foucar; 11. Lymphoma Jennifer Herrick and Ahmet Dogan; 12. Plasma cell neoplasms Rafael Fonseca and Riccardo Valdez; 13. Chronic myeloid leukemia Emma J. Gudgin and Brian Huntly; 14. Myeloproliferative neoplasms Philip A. Beer and Anthony R. Green; 15. Myelodysplastic syndromes and myelodysplastic/myeloproliferative ...
This chapter gives the description on hematology, which is given in the question and answer format. A hemoglobin molecule is conjugated protein composed of iron containing pigment called heme and protein globin. About 65-70% of hemoglobin is synthesized in normoblasts and 30-35% is synthesized at the reticulocyte stage. This chapter covers the anemia, iron deficiency anemia (IDA), macrocytic anemia, pernicious anemia, hemolytic anemia, defects in hemoglobin production, sickle cell disease, hereditary spherocytosis, thalassemia syndrome, glucose-6-phosphate dehydrogenase (G6PD) deficiency, miscellaneous anemia, non-neoplastic disorders of WBC, acute leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative neoplasms, plasma cell neoplasms, Hodgkin lymphoma, hemostasis, bleeding disorders (hemorrhagic diatheses), thrombocytopenia, qualitative platelets defects, immune thrombocytopenic purpura, thrombocytosis, disorders of coagulation (clotting), fibrinolysis, ...
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
Expert Perspective. Given the frequency of a neutrophilic leukemoid reaction in association with plasma cell myeloma and monoclonal gammopathy of undetermined significance, the bone marrow should be examined for evidence of a plasma cell neoplasm in all cases of suspected CNL.1,6 If a plasma cell neoplasm is present (and CSF3R T6181 or another activating CSF3R mutation is absent1), only then is demonstration of clonality of myeloid cells by cytogenetic or molecular studies advocated (Choice B is incorrect).1 Complete cytogenetic remission with imatinib was reported in a patient with CNL associated with t(15;19)(q13;p13.3), suggesting the possibility of an unidentified fusion gene in some cases of CNL1,7 (Choice C is correct).. Acknowledgment: Faiz Ahmed Hussain, MD, of the Department of Internal Medicine, Jackson Park Hospital, Chicago, assisted in preparing this review.. DISCLOSURE: Dr. Abutalib is on the advisory board of Juno Pharmaceuticals. Dr. Medeiros reported no conflicts of ...
Plasma cell myeloma can be either localised (solitary plasmacytoma; 30%) or generalised (multiple myeloma; 70%). Solitary plasmacytoma may arise from either in bone or in extramedullary tissues (7). Solitary plasmacytoma is rare and accounts for 5-10 % of plasma cell disorders (1). About a half of solitary plasmacytomas of bone occur in the spine, especially in the thoracic region, and rarely in the skull (1, 2). It was reported that these cases occurred primarily in the parietal bone, occipital bone, frontal bone, temporal bone and the skull base is an extremely rare site (8). Until now, only two cases were reported in the sphenoid bone (8). Criteria for the diagnosis include (a) a solitary bone lesion, (b) bone marrow plasmacytosis less than 10%, (c) biopsy evidence of plasma cell neoplasm and (d) absence of evidence of other lesions based on clinical examination or skeletal survey. The CT features reported by some authors (3, 4) are characterized by osteolytic lesion without sclerotic rim, ...
Title:The Role of miRNAs in Plasma Cell Dyscrasias. VOLUME: 2 ISSUE: 3. Author(s):Siobhan Glavey, Salomon Manier, Antonio Sacco, Giuseppe Rossi, Irene M. Ghobrial and Aldo M. Roccaro. Affiliation:Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.. Keywords:MGUS, miRNA, multiple myeloma, plasma cell, regulation, waldenstroms macroglobulinemia.. Abstract:Plasma cell dyscrasias are a group of related disorders that have in common the clonal proliferation of plasma cells with resultant production of a monoclonal immunoglobulin that can be detected on serum protein electrophoresis (M-spike). This term incorporates the Plasma Cell Neoplasms along with other related disorders that are not considered malignant. Comprehensive genomic studies have greatly advanced our understanding of the genetic complexity of these diseases in recent years, however they continue to be considered incurable with a highly heterogeneous phenotype. It is clear that a deeper level of knowledge of the ...
Abstract:. Introduction: Primary plasmacytoma of the thyroid gland is a rare disease. Extramedullary plasmacytoma (EMP) comprises 3-5% of all plasma cell neoplasm. Case report: A 57-yearsold female presented with a large thyroid swelling involving the left lobe and isthmus, firm in consistency and moved a little with deglutition. CT scan revealed a large solid tumor (9.5 cm in greatest dimension) affecting thyroid gland. CT scan report gave differential diagnoses of plasmacytoma and metastatic carcinoma. FNAC revealed hypercellular smears composed of plasma cells with eccentrically placed nuclei and perinuclear hoff. Hematological work up and other relevant investigations including urine for Bence Jones protein ruled out multiple myeloma or other plasma cell dyscrasias. Subsequent histopathological examination and IHC (immunohistochemistry) confirmed the diagnosis of primary plasmacytoma of thyroid. Discussion: EMP can present with elevated anti thyroid antibodies and can be associated with ...
Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. When plasma cells become cancerous and grow out of control, this is called multiple myeloma. See Plasma Cell Neoplasm/Multiple Myeloma for signs, symptoms and treatments.. ...
Solitary plasmacytoma is plasma cell neoplasm. It is a localized bone disease and for this reason it is different from multiple myeloma (systemic plasma cell
INTRODUCTION The plasma cell neoplasms may present in soft tissue as extramedullary plasmacytoma (EMP), in bone as a solitary plasmacytoma of bone (SPB), or as part of the multifocal disseminated disease multiple myeloma (MM). These tumors are derived from bone marrow stem cells of B-Lymphocyte lineage, and are characterized by an expansion of a clone of immunoglobulin-secreting cells (Regezi et al., 2003).. Multiple Mieloma (MM). The MM represents the most important and common plasma cell dyscrasia (Regezi et al.), involving large numbers of bone (Shafer et al., 1974). Also known as generalized myeloma or myelomatosis, its etiology is unknown, it is characterized by the proliferation of cells that have the microscopic appearance of plasmacytes (Anil, 2007). It is considered a multifocal plasma cell cancer of the skeleton, but it may also affect extraskeletal sites during its progression (Dores et al., 2009). The disease begins insidiously in bone marrow, and by the time it is diagnosed it is ...
Lymphoproliferative disorders (LPDs) can be parsed into the following 6 categories: Hodgkin disease Non-Hodgkin lymphoma Histiocytosis X Benign reactive lymphoproliferative disorders (including posttransplantation lymphoproliferative disorder [PTLD]) Plasma cell neoplasms Cutaneous T-cell lymphoma (mostly in heart, pancreas and bone marr...
Multiple Myeloma (MM) is a plasma cell neoplasm that responds well to therapeutic agents such as bortezomib, a proteasome inhibitor, and lenalidomide, an immunomodulatory drug. However, myeloma patients acquire resistance to these agents and disease relapses. Previously, it has been established that levels of hepatocyte growth factor (HGF) are high in serum of myeloma patients. In concert, our studies in myeloma indicated that HGF gene expression is also high in CD138+ myeloma plasma cells. High HGF levels in serum and in myeloma cells are correlated with poor prognosis and advanced disease. HGF is the ligand for the MET receptor tyrosine kinase that controls proliferation, survival and migration. Our earlier studies demonstrated that MET acts as a survival factor in myeloma cells. We hypothesized that MET/HGF axis may serve as a resistant mechanism in myeloma. To test this, we examined the HGF/MET signaling pathway in bortezomib and lenalidomide resistant myeloma cell lines. These lines were ...
TY - JOUR. T1 - Gene signature combinations improve prognostic stratification of multiple myeloma patients. AU - Chng, W. J.. AU - Chung, T. H.. AU - Kumar, Shaji K. AU - Usmani, S.. AU - Munshi, N.. AU - Avet-Loiseau, H.. AU - Goldschmidt, H.. AU - Durie, B.. AU - Sonneveld, P.. PY - 2015/12/16. Y1 - 2015/12/16. N2 - Multiple myeloma (MM) is a plasma cell neoplasm with significant molecular heterogeneity. Gene expression profiling (GEP) has contributed significantly to our understanding of the underlying biology and has led to several prognostic gene signatures. However, the best way to apply these GEP signatures in clinical practice is unclear. In this study, we investigated the integration of proven prognostic signatures for improved patient risk stratification. Three publicly available MM GEP data sets that encompass newly diagnosed as well as relapsed patients were analyzed using standardized estimation of nine prognostic MM signature indices and simulations of signature index combinations. ...
Multiple myeloma is an entity of cytogenetically and genetically heterogenous plasma cell neoplasms. Despite recent improvement in the treatment outcome of multiple myeloma by novel molecular-targeted chemotherapeutics, multiple myeloma remains incurable. The identification of a therapeutic target molecule in which various signaling for cell-survival converge is a core component for the development of new therapeutic strategies against multiple myeloma. RSK2 is an essential mediator of the ERK1/2 signaling pathway for cell survival and proliferation. In this study, we discovered that RSK2Ser227, which is located at the N-terminal kinase domain and is one site responsible for substrate phosphorylation, is activated through phosphorylation regardless of the type of cytogenetic abnormalities or upstream molecular signaling in all 12 multiple myeloma-derived cell lines examined and 6 of 9 patient-derived CD138-positive primary myeloma cells. The chemical inhibition of RSK2Ser227 by BI-D1870 or gene ...
Plasma cell neoplasms (including multiple myeloma) treatment include observation, chemotherapy, radiation, stem cell rescue, targeted, and supportive therapies. Corticosteroids and immunomodulatory drugs may be used. Get detailed treatment information in this summary for clinicians.
Here is the list of cancers that are covered by the World Trade Center Health Program:. Childhood Cancers, Malignant Neoplasms, Blood and Lymphoid Tissue (including, but not limited to, lymphoma, leukemia, and myeloma) Diffuse non-Hodgkin , Follicular (nodular) non-Hodgkin lymphoma, Hodgkins disease, Leukemia of unspecified cell type, Lymphoid leukemia, Malignant immunoproliferative diseases, Monocytic leukemia, Multiple myeloma and malignant plasma cell neoplasms, Myeloid leukemia, Hodgkin lymphoma, Other leukemias of specified cell type, Peripheral and cutaneous T-cell lymphoma, Digestive System, Colon, Esophagus, Liver and intrahepatic bile ducts, Other and ill-defined digestive organs, Rectosignoid junction, Rectum, Retroperitoneum and peritoneum, Stomach, Eye and Orbit, Eye and adnexa, Breast Ovarian, Head and Neck, Accessory sinuses, Base of tongue, Floor of mouth, Gum, Hypopharynx, Larynx, Lip, Nasal cavity, Nasopharynx, Other and ill-defined conditions in the lip, oral cavity, and ...
Mandel, M A. and Cosse, J J., Effect of anti-thymocyte sera on the growth of plasma cell tumors in mice. Abstr. (1969). Subject Strain Bibliography 1969. 139 ...
Learn about the causes, symptoms, diagnosis & treatment of Plasma Cell Disorders from the Professional Version of the Merck Manuals.
Multiple myeloma (MM) remains an incurable clonal plasma cell malignancy. The existence of cancer stem cell-like subpopulation in MM may explain for its unfavourable prognosis and high relapse rate. Studies have shown that CD138neg MM cells were clonogenic and could be serially transplanted, while CD138+ cells could not. We characterized CD138neg cells by checking the presence of such subpopulation and their tumorigenic properties. In concordance with literature, CD138neg cells were present in MM cell lines, and possessed higher clonogenic potential than its non-tumorigenic counterpart as shown in colony formation assay. They were more quiescent, with less than 1% in G2/M phase compared to 5-10% in CD138+ cells. They also demonstrated higher resistance to chemotherapeutic agents, including thalidomide and bortezomib. Since studies in solid tumors have demonstrated that microRNA (miRNA) plays a role in self-renewal, tumorigenicity and chemoresistance in cancer stem cells, we hypothesized that ...
Plasma cell dyscrasias are disorders of the plasma cells. Plasma cell dyscrasias are produced as a result of abnormal proliferation of a monoclonal population of plasma cells that may or may not secrete detectable levels of a monoclonal immunoglobulin or immunoglobulin fragment (paraprotein or M protein). Although the most common plasma cell dyscrasia is monoclonal gammopathy of undetermined significance (MGUS), closely related disorders include multiple myeloma, solitary plasmacytoma of bone, extramedullary plasmacytoma, Waldenströms macroglobulinemia (WM), primary amyloidosis, light chain deposition disease, paraproteinemia, and heavy-chain disease. The spectrum of MGUS, solitary plasmacytoma of bone, and asymptomatic and symptomatic multiple myeloma may actually represent a natural progression of the same disease. ...
IRVING, Texas, Dec. 3, 2010 (GLOBE NEWSWIRE) -- Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, announced that Dr. Raul Braylan, Hematopathologist and Clinical Medical Director of Hematopathology Services, will present key findings related to plasma cell disorders at the upcoming 52nd Annual Meeting and Exposition of the American Society of Hematology. Dr. Braylan will present data validating the clinical utility of Caris approach to flow cytometric analysis in the routine diagnostic evaluation of patients with plasma cell disorders, such as multiple myeloma.
This is the first study to show the preclinical utility and translational relevance of the iMycCα/Bcl-XL GEM model of PCM. We showed that MLN2238 prolonged overall survival, reduced splenomegaly, and attenuated IgG2a levels of iMycCα/Bcl-XL mice after only 6 weeks of treatment. Nevertheless, comparing the average immunoglobulin and cytokine levels from mice reaching humane endpoints across different treatment groups has it limitations. Linden and colleagues showed that similar to human multiple myeloma where elevation of serum immunoglobulin often precedes the manifestation of malignant diseases, the single Bcl-XL TG alone can lead to immunoglobulin elevations in the absence of PCM (25). Given the stochastic nature of tumor development and heterogeneity of immunoglobulin elevations in the iMycCα/Bcl-XL model (Supplementary Table S2), it is not surprising that the current cross-sectional manner of comparing the average immunoglobulin levels across different treatment groups at the end of the ...
Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the epidermis, the dermis, or the subcutis, resulting in clinically identifiable cutaneous lesions. The appearance of these lesions is variable and may include flesh-colored-to-violaceous papules, plaques, or nodules.
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a geriatric assessment, as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244 ...
Türk Hematoloji Okulunun üçüncü dönemi dördüncü kursu EHA-TSH Hematology Tutorial on Plasma Cell Disorders (excluding the classical multiple myeloma) 19-20 Mart 2016 tarihlerinde Kuşadasında düzenlendi.. Yurtdışı ve yurtiçinden değerli konuşmacıların katıldığı bu kurs, Avrupa Hematoloji Derneği ortaklığı ile gerçekleştirilen altıncı kurs oldu. ...
Lymphocyte and plasma cell disorders can be classified into three major groups (Table 78-1). The first group, listed under primary disorders, is composed of lymphocyte disorders caused by intrinsic defects in lymphoid cells that result in functional abnormalities of marrow-derived (B) lymphocytes, thymic-derived (T) lymphocytes, combined T and B (impaired humoral and cellular immunity), or natural killer (NK) cells. These disorders primarily result from inborn errors in lymphocyte metabolism (Chaps. 73 to 77 and 80) and/or receptor-ligand expression (Chaps. 17 and 80). The second group, listed under acquired disorders, consists of disorders caused by factors extrinsic to lymphocytes resulting in immune dysfunction. These conditions most commonly result from infection with viruses, or other cellular pathogens (Chaps. 79, 81, and 82), but they also may be caused by bacteria, drugs or systemic disease of nonlymphoid cells. The third group of diseases is composed of preneoplastic and neoplastic ...
Merck & Co., Inc., Kenilworth, NJ, USA is a global healthcare leader working to help the world be well. From developing new therapies that treat and prevent disease to helping people in need, we are committed to improving health and well-being around the world. The Merck Manual was first published in 1899 as a service to the community. The legacy of this great resource continues as the Merck Manual in the US and Canada and the MSD Manual outside of North America. Learn more about our commitment to Global Medical Knowledge.. ...
Infectious Disease Advisor is used by specialists and other medical professionals to help understand and treat infectious diseases. Latest news, research and treatment articles.
This graph shows the total number of publications written about Neoplasms, Plasma Cell by people in this website by year, and whether Neoplasms, Plasma Cell was a major or minor topic of these publications ...
Kaheksa tüüpi ravi kasutatakse. keemiaravi. Keemiaravi on vähiravi mis kasutab narkootikume peatada vähirakkude kasvu, kas tappes rakke või peatades neid pooldumist. Keemiaravi võtta suu kaudu või süstitakse veeni või lihasesse, narkootikumid siseneda vereringesse ja jõuavad vähirakke kogu keha (süsteemset keemiaravi). Keemiaravi paigutatud otse tserebrospinaalvedelik, elundi või kehaõõnde nagu kõhu-, narkootikumid mõjutavad peamiselt vähirakkude nendes piirkondades (piirkondlikud keemiaravi). See, kuidas keemiaravi antakse sõltub liigist ja etapi ravitavaks vähiks.. Vaata heaks kiidetud ravimid Multiipelmüeloom ja muud Plasma Cell kasvajad rohkem teavet.. Muud medikamentoossele ravile. Kortikosteroidid steroidid, millel on kasvajavastane toime hulgimüeloomis.. Suunatud ravi. Suunatud ravi on ravi, mis kasutab narkootikume või muude ainete tuvastamiseks ja rünnak konkreetsete vähirakke ilma normaalseid rakke kahjustamata. Proteasoomi inhibiitoriga on teatud tüüpi ...
AIMS: To investigate the immunohistochemical expression of CD31 (JC70) in normal and neoplastic plasma cells. METHODS: Plasma cells in bone marrow biopsies and extramedullary locations were examined. All extramedullary biopsies were formalin fixed and paraffin embedded. The bone marrow biopsies were fixed in formal acetic acid and embedded in paraffin wax. Twenty multiple myelomas (12 bone marrow and eight extramedullary deposits), 10 extramedullary plasmacytomas, and 30 biopsies with reactive plasma cells (10 bone marrow, 20 extramedullary biopsies) were stained with anti-CD31 (JC70) using the streptavidin-biotin detection system with diaminobenzidine as a chromogen. Antigen retrieval in bone marrow biopsies was achieved by pressure cooking. In all other biopsies, antigen retrieval was achieved by microwave pretreatment. RESULTS: All 20 extramedullary cases with reactive plasma cells showed intense membrane staining. Focal staining was detected in reactive plasma cells in bone marrow biopsies. ...
Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the skin resulting in clinically identifiable cutaneous lesions. This condition may be contrasted with leukemids, which are skin lesions that occur with leukemia, but which are not related to leukemic cell infiltration. Leukemia cutis can occur in most forms of leukemia, including chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and prolymphocytic leukemia. Granulocytic sarcoma List of cutaneous conditions James, William Daniel; Berger, Timothy G.; Elston, Dirk M. (2006). Andrews Diseases of the Skin: clinical Dermatology. Saunders Elsevier. pp. 744-5. ISBN 0-7216-2921-0. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. p. 1892. ISBN 1-4160-2999-0. Leukemia Cutis at ...
TY - JOUR. T1 - Diagnostic utility of S100A1 expression in renal cell neoplasms. T2 - An immunohistochemical and quantitative RT-PCR study. AU - Rocca, Paolo Cossu. AU - Brunelli, Matteo. AU - Gobbo, Stefano. AU - Eccher, Albino. AU - Bragantini, Emma. AU - Mina, Maria M.. AU - Ficarra, Vincenzo. AU - Zattoni, Filiberto. AU - Zamò, Alberto. AU - Pea, Maurizio. AU - Scarpa, Aldo. AU - Chilosi, Marco. AU - Menestrina, Fabio. AU - Bonetti, Franco. AU - Eble, John N.. AU - Martignoni, Guido. PY - 2007/7/1. Y1 - 2007/7/1. N2 - S100A1 is a calcium-binding protein, which has been recently found in renal cell neoplasms. We evaluated the diagnostic utility of immunohistochemical detection of S100A1 in 164 renal cell neoplasms. Forty-one clear cell, 32 papillary, and 51 chromophobe renal cell carcinomas, and 40 oncocytomas, 164 samples of normal renal parenchyma adjacent to the tumors and 13 fetal kidneys were analyzed. The levels of S100A1 mRNA detected by quantitative RT-PCR analysis of frozen tissues ...
TY - JOUR. T1 - Pre-pubertal and adolescent germ cell neoplasms in Taiwan. T2 - Time trends and geographic variation. AU - Hung, G. Y.. AU - Horng, J. L.. AU - Yen, H. J.. AU - Lee, C. Y.. PY - 2015/9/1. Y1 - 2015/9/1. N2 - Evidence from our previous study suggested that the incidence of germ cell neoplasms in children and adolescents is increasing. The objectives of this analysis were to quantify this trend in patients aged 0-9 and 10-19 years (pre-pubertal and adolescent groups, respectively) and compare rates in Taiwan according to geographic distribution. Germ cell neoplasm frequencies among 1267 patients aged 0-19 years spanning 1995-2009 were obtained from the population-based Taiwan Cancer Registry. The incidence patterns according to sex, age, disease subgroup, and geographic distribution were analyzed. The incidence rates in the pre-pubertal and adolescent groups were 10.58 and 16.06 per million person-years, respectively. The overall rates increased significantly by 3.2% annually in ...
We have investigated the importance of glycosylation in determining the function of membrane-bound and secreted immunoglobulin M (IgM). Hickman and Kornfeld (1978) previously observed that glycosylation is required for IgM to be secreted by 104E, a mouse plasma cell tumor. In order to determine whether this requirement is a general one for all forms of IgM, we have used WEHI 279.1, a mouse B lymphoma that synthesizes both the membrane and secreted forms of IgM. In the presence of 5 microgram/ml tunicamycin (Tm), glycosylation of both membrane and secreted IgM is at least 90% inhibited, but total protein synthesis is equivalent in control and Tm-treated cells. Despite the absence of carbohydrate, IgM molecules are properly assembled into monomers for membrane localization. Cells whose surfaces have been stripped of membrane IgM by treatment with anti-mu antibody resynthesize the IgM equally well in the presence or absence of Tm. It is more surprising that the assembly of IgM into pentamers and the
Leukemia Cutis Mimicking Kerion Celsi: A challenging Diagnosis for Clinicians, Kartal D, Levent Çà ±nar S, Gül Kà ±rkaà  &O
TY - JOUR. T1 - Plasma cell satellitism in plasma cell myeloma [6]. AU - Dimov, N. D.. AU - Zynger, D. L.. AU - Peterson, L. C.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2006/9. Y1 - 2006/9. UR - http://www.scopus.com/inward/record.url?scp=33748857788&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=33748857788&partnerID=8YFLogxK. U2 - 10.1136/jcp.2005.034710. DO - 10.1136/jcp.2005.034710. M3 - Letter. C2 - 16935984. AN - SCOPUS:33748857788. VL - 59. SP - 1003. JO - Molecular pathology : MP. JF - Molecular pathology : MP. SN - 0021-9746. IS - 9. ER - ...
Definition of plasma cell myeloma. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
[Multiple myeloma is a multifaceted haematological disease, a plasma cell malignancy that may pose an oncological differential diagnostic challenge. The importance of this disease is emphasized by its incidence. Since there are multiple novel therapies available for myeloma patients, decade-long survival in not uncommon; therefore, myeloma patients provide a signifi cant part of the patients referred to hematological clinics. In this review, fi rst the novel diagnostic criteria are introduced, followed by the standard therapeutic approaches for transplant-eligible and ineligible patients. As the disease nearly always relapses, the later line therapies available in this malignancy are presented with a special emphasis on the Hungarian haematological practice.]
This phase II trial investigates whether patients |= 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes
Monoclonal Antibody Therapy in Multiple Myeloma: Where Do We Stand and Where Are We Going? A new publication in the journal Immunotherapy (monthly peer-reviewed journal covering immunology and immunotherapy) 2016 Mar; 8 (3): 367-84 Primary Author: Sharmilan Thanendrarajan, M.D., Assistant Professor Abstract Multiple myeloma is a plasma cell malignancy that is characterized by refractory and relapsing course…. ...
The expression of a wide range of chemokine ligands for CXCR3 and CCR4 was markedly increased within the bone marrow of patients with MGUS and MM compared to healthy donors. The most marked effects were seen for CCL4 and CXCL9 which were increased by 4 and 6 fold respectively in the bone marrow of patients with myeloma. The expression of CXCR3 and CCR4, the major TH1 and TH2-associated chemokine receptors, was increased substantially on T cells within the bone marrow of patients whereas the percentage of CXCR3-expressing T cells within blood was correspondingly decreased. The presence of even small numbers of neoplastic plasma cells or associated stroma can therefore generate an inflammatory chemokine tumour microenvironment. This leads to the selective recruitment or retention of specific T cell subsets which is likely to underlie many of the features regarding the peripheral T cell repertoire in myeloma and may also contribute to the immune suppression associated with this disease. This local ...
Copyright © 2019 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer and privacy policy. ...
Neoplasms of immune cells, which include the leukemias, the lymphomas, and the plasma cell tumors, are less common but much more important clinically. Hodgkin lymphoma (the first of these tumors to be described) came to attention in 1832 in a paper entitled On Some Morbid Appearances of the Absorbent Glands and Spleen by Thomas Hodgkin. The photograph on the right illustrates the natural history of Hodgkin lymphoma, which includes the inexorable development of massively enlarged lymph nodes and eventual spread of the disease to the liver, spleen, bone marrow, and other tissues. Little could be done for such unfortunate souls. ...
Multiple myeloma, also known as plasma cell myeloma or Kahlers disease, is a type of abnormal growth of plasma cells collected in the bone marrow where they grow and multiple to interfere with the production of normal blood cells. Paraprotein, an abnormal antibody produced by the plasma cell myeloma not only can cause kidney problem …. ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Multiple myeloma (MM), a malignancy of plasma cells, accounts for ~13% of all hematological malignancies. Many genes have been identified in the pathogenesis of MM including interferon regulatory factor 4, IRF4, a proto-oncogene. IRF4 is a transcription factor activated by the NF-кB pathway and is a regulator of plasmacytic differentiation and cell cycle progression amongst … [Read more…]. ...
Twenty-six patients with JDM (14 male, 12 female) were included in this study. 73% of biopsies (n=19) contained CD20+ B cells while only 26% of biopsies (n=7) contained CD138+ plasma cells. The score for CD20+ cells was strongly correlated with the score for CD3+ cells (r=0.81; p,0.0001) and the inflammatory domain score (r=0.87; p,0.0001). Among those biopsies that contained CD138+ plasma cells, the CD138+ score was correlated with the score for CD20+ cells (r=0.89; p=0.026), the score for CD3+ infiltrating cells (r=1.0; p,0.0001) and the inflammatory domain score (r=0.84; p=0.015). In most cases, B cells were co-localised with T cells especially at perivascular and endomysial regions but in some cases they were diffusely scattered. No specific patterns were observed for plasma cells which were found as individual scattered cells mainly in the perimysium. ...
Like all lymphocytes plasma cells possess a large unlobulated nucleus, justifying their classification as Mononuclear Cells. To maintain their enormous synthetic and secretory activity, Plasma Cells possess an expanded Endoplasmic Reticulum. To accommodate this expanded organelle, Plasma Cells possess a more prominent cytosol than do most lymphocytes ...
Myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Initially, often no symptoms are noticed. When advanced, bone pain, bleeding, frequent infections, and anemia may occur. Complications may include amyloi
Plasma cell definition, Anatomy. an antibody-secreting cell, derived from B cells, that plays a major role in antibody-mediated immunity. See more.